Most recently, MEL enhanced the efficacy of sorafenib against pancreatic cancer by downregulation of PDGFR-β/STAT3 cell signaling and MEL receptor (MT)-mediated STAT3 in PDAC cells [131]. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.